What is Fennec Pharma?
Fennec Pharmaceuticals Inc., headquartered in Research Triangle Park, North Carolina, is a biopharmaceutical firm focused on developing and commercializing treatments to mitigate hearing loss associated with platinum-based chemotherapy, particularly in pediatric patients. The company's lead product, PEDMARK®, a formulation of sodium thiosulfate, has received FDA approval for preventing platinum-induced ototoxicity in children with localized, non-metastatic solid tumors. An adapted version, PEDMARQSI®, has gained authorization for pediatric use in Europe and the UK, with international commercialization managed through a licensing agreement with Norgine Pharmaceuticals Ltd. This strategic positioning highlights Fennec Pharma's commitment to addressing critical unmet needs in pediatric oncology supportive care.
How much funding has Fennec Pharma raised?
Fennec Pharma has raised a total of $45M across 1 funding round:
Private Equity
$45M
Private Equity (2022): $45M with participation from Petrichor Healthcare Capital Management
Key Investors in Fennec Pharma
Petrichor Healthcare Capital Management
Petrichor Healthcare Capital Management is a private equity firm that provides capital solutions for the healthcare industry. Their investment in Fennec Pharma suggests a focus on commercial-stage biopharmaceutical companies with approved products.
What's next for Fennec Pharma?
The recent major strategic investment provides Fennec Pharma with substantial resources to advance its commercialization efforts and potentially expand its therapeutic pipeline. This capital infusion is expected to accelerate market penetration for PEDMARK® and PEDMARQSI®, particularly in key international markets. The company's focus on a niche but critical area of pediatric cancer treatment, coupled with regulatory approvals, positions it for significant growth. Future developments may include further clinical studies, expanded indications, or strategic partnerships to enhance its global reach and impact on patient care.
See full Fennec Pharma company page
